Bisphosphonate Functionalized Gadolinium Oxide Nanoparticles Allow Long-Term MRI/CT Multimodal Imaging of Calcium Phosphate Bone Cement by Mastrogiacomo, Simone et al.
www.advhealthmat.de
COMMUNICATION
1800202 (1 of 9) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Bisphosphonate Functionalized Gadolinium Oxide 
Nanoparticles Allow Long-Term MRI/CT Multimodal 
Imaging of Calcium Phosphate Bone Cement
Simone Mastrogiacomo, Alicja E. Kownacka, Weiqiang Dou, Benjamin P. Burke, 
Rafael T. M. de Rosales, Arend Heerschap, John A. Jansen, Stephen J. Archibald,*  
and X. Frank Walboomers*
DOI: 10.1002/adhm.201800202
In the field of tissue engineering (TE) and 
regenerative medicine (RM), biological 
constructs have reached such a high simi-
larity with native tissues that conventional 
imaging techniques tend to be inadequate 
for their detection.[1] However, it is of key 
importance to be able to monitor the per-
formance of the material over the course 
of an in vivo trial. Therefore, there is a 
pressing need for the development of inno-
vative noninvasive imaging approaches, for 
example, based on multimodal imaging 
strategies combining magnetic resonance 
imaging (MRI) and computed tomography 
(CT).[2] For example, calcium phosphate–
derived cements (CPCs)—a class of advanced 
injectable and biodegradable bone substi-
tutes—show such high structural similarity 
with the mineral phase of mammalian 
osseous tissue that their detection is ham-
pered.[3] On conventional radiographs, CPC 
has similar radiopacity to cortical bone and 
a slightly more radiodense appearance than 
the surrounding trabecular bone, making 
the monitoring of the material perfor-
mance over clinically relevant periods both 
problematic and inaccurate.[4]
Direct in vivo monitoring of bioconstructs using noninvasive imaging modali-
ties such as magnetic resonance imaging (MRI) or computed tomography 
(CT) is not possible for many materials. Calcium phosphate–based compos-
ites (CPCs) that are applicable to bone regeneration are an example where 
the materials have poor MRI and CT contrast; hence, they are challenging to 
detect in vivo. In this study, a CPC construct is designed with gadolinium-
oxide nanoparticles incorporated to act as an MRI/CT multimodal contrast 
agent. The gadolinium(III) oxide nanoparticles are synthesized via the polyol 
method and surface functionalized with a bisphosphonate (BP) derivative to 
give a construct (gadolinium-based contrast agents (GBCAs)-BP) with strong 
affinity toward calcium phosphate. The CPC-GBCAs-BP functional material 
is longitudinally monitored after in vivo implantation in a condyle defect 
rat model. The synthetic method developed produces nanoparticles that 
are stable in aqueous solution (hydrodynamic diameter 70 nm) with signifi-
cant T1 and T2 relaxivity demonstrated in both clinical 3 T and preclinical 
11.7 T MRI systems. The combination of GBCAs-BP nanoparticles with CPC 
gives an injectable material with handling properties that are suitable for 
clinical applications. The BP functionalization prolongs the residence of the 
contrast agent within the CPC to allow long-term follow-up imaging studies. 
The useful contrast agent properties combined with biological compatibility 
indicate further investigation of the novel bone substitute hybrid material 
toward clinical application.
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The demand for noninvasive imaging modalities makes MRI 
an ideal technique as it allows noninvasive anatomical imaging 
and functional 3D visualization of soft tissues with high spa-
tial resolution. Imaging of CPCs using the magnetic resonance 
(MR) modality can be achieved by application of short or zero 
echo time acquisition sequences (i.e., ulthrashort echo time 
(UTE) and zero echo time (ZTE), respectively), which acquire 
data quasi-simultaneously with the excitation pulse. Neverthe-
less, due to similar transverse relaxation values between cortical 
bone and CPC (i.e., T2 < 1 ms), the contrast is not sufficient for 
the material characterization in vivo, thus incorporation of addi-
tional agent component is required.[5]
Gadolinium(III) is a lanthanide element with seven unpaired 
electrons and a symmetric S-state, and it shortens T1 relaxation 
times of the water in tissues in which it is taken up, leading 
to a signal enhancement in T1-weighted MRI due to this para-
magnetic properties.[6] Commercially available gadolinium(III)-
based contrast agent (GBCAs) have already been utilized to 
enhance the T1 signal of CPC constructs in vivo.[7] However, 
the strategy employed which utilized molecular agents that 
were not strongly linked to the material showed an insufficient 
performance level that did not meet the required contrast and 
longitudinal imaging properties. The CPC degradation pro-
file in vivo and the highly porous nature of the material led to 
leaching of the contrast agent, limiting long-term monitoring 
properties. Therefore, in order to improve the contrast prop-
erties in both CT and MRI the use of gadolinium(III) nano-
particles (NPs) versus molecular agents offers more efficient 
relaxivity, higher effective concentrations, and the potential to 
more firmly anchor the contrast agent into the material.
Bisphosphonates (BPs) are well known for their bone-tar-
geting properties. Functionalization of pharmaceutics (e.g., 
osteoprotegerin) or nanoparticles (e.g., superparamagnetic iron 
oxide) with BP groups allows them to strongly interact with 
the hydroxyapatite mineral phase of the bone offering mul-
tiple bonding interactions with calcium ions (Ca2+) from each 
BP component.[8] These interactions can be used to specifically 
bind the GBACs into the CPC matrix and prolong the residence 
of the imaging probe in situ, despite the on-going material deg-
radation. To date, the CPC binding and targeting properties of 
BP remain unexplored.
Thus, in the presented study, we have developed a sur-
face functionalized GBCAs that can be used for long-term 
noninvasive monitoring of a specific CPC composite (i.e., 
mix of alpha-tricalcium phosphate, α-TCP, cryo-grinded 
poly(D,L-lactide-co-glycolide) microparticles, PLGA, and 
carboxy methylcellulose, CMC, see Experimental Section in 
the Supporting Information). To this end, gadolinium oxide 
(Gd2O3) nanoparticles (<5 nm in diameter) for multimodal 
MR/CT imaging were synthesized via the polyol method. Sur-
face functionalization of the nanoparticles to encapsulate them 
in a mesoporous silica shell by addition of 3-glycidyloxypropyl 
trimethoxysilane (GPTES) was used to stabilize the system in 
aqueous media and to facilitate further functionalization with 
BP derivatives. The presence of the BP groups in the final con-
structs enhanced the affinity toward the hydroxyapatite, the 
main component of the CPC composite, and created the CPC-
specific contrast agent (Scheme 1). Elemental analysis and IR 
spectroscopy was used to characterize the BP functionalization 
of the GBCAs, while in vitro binding experiments confirmed 
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Scheme 1. Schematic illustration of the GBCA-BP synthesis and combination within the CPC. The multidentate bonding interaction between the phos-
phonate groups from the BP derivative and the calcium ions from the CPC increases the affinity of GBCA-BP to the mineral phase of CPC.
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the high affinity of the BP functionalized GBCAs (GBCAs-BP) 
toward the solid state CPC. After in vitro toxicity tests and char-
acterization of the handling and mechanochemical properties, 
the obtained CPC-GBCAs nanocomposite was implanted in 
vivo in a rat model and the behavior of the material was fol-
lowed by CT and MRI. The dual-modality nanoparticle probe 
allowed the visualization of the implanted cement for the 
entire experimental time course of 8 weeks. Finally, histological 
assessments were performed to investigate the biological effect 
of the applied material on the surrounding bone tissues and 
showed no adverse reactions or inhibition of bone formation.
To form contrast agent, gadolinium oxide nanoparticles 
were coated with a biocompatible stable silica layer that gives 
high colloidal stability and contains epoxy rings (from GPTES) 
which were used to react with the bisphosphonate precursor 
and functionalize the surface of the GBCAs (Scheme 1).[9] 
Elemental analyses (carbon, hydrogen, and nitrogen (CHN) 
combustion analysis and inductively coupled plasma optical 
emission spectroscopy, ICP-OES) were performed on the 
nanoparticles before and after functionalization, showing 
the chemical modification of the surface of the nanoparti-
cles at each synthetic step (Figure 1). The results from before 
and after addition of GPTES offered an assessment of the 
amount of silica polymerized on the nanoparticles surface. 
Thus, allowing an estimation of the molar amount of epoxide 
groups available for covalent conjugation with BP derivative. 
As expected, analysis of the resulted nanoparticles showed a 
decrease in the percentage of gadolinium(III) and an increase 
Adv. Healthcare Mater. 2018, 7, 1800202
Figure 1. Chemical and morphological characterization of the synthesized nanoparticles. a) Table summarizing the elemental analysis results for the 
particles after the polyol synthesis, after GPTES stabilization and after BP functionalization, respectively. CHN analysis was performed by combustion 
using a CHN analyzer, while Gd and P were quantified by ICP-OES. Si content was determined by energy-dispersive X-ray spectroscopy using defined 
regions of interest from the TEM image. b) TGA analysis of the GBCAs after GPTES coating. c) TEM of GBCAs-BP. Yellow circles define a single particle. 
d–f) Fourier-transform infrared spectroscopy spectrum of the particles after the polyol synthesis, after GPTES coating, and after BP functionalization, 
respectively.
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of the organic component (Figure 1a). The presence of carbon 
in the “uncoated” gadolinium oxide sample is due to the dieth-
ylene glycol, which is used as a solvent in the reaction as it 
adsorbs onto nanoparticles surface via interactions with the 
hydroxyl group stabilizing the NPs in solution.[10] The detec-
tion of nitrogen and phosphorous in the final product (i.e., 
GBCAs-BP) indicated the presence of the BP derivative on the 
surface of the nanoparticles. Thermogravimetric analysis (TGA, 
Figure 1b) was used to assess the overall mass of the organic 
layer, which was found to be around 30% of the total weight. 
Transmission electron microscopy (TEM) showed a slight size 
increase (≈1–2 nm) of the Gd2O3 nanoparticles core size after 
GPTES coating, while no differences were observed after BP 
functionalization (Figure S1, Supporting Information). GBCA-
BP nanoparticles were shown to have homogeneous size 
and morphology with a final core diameter less than 5 nm 
(Figure 1c), while the measured hydrodynamic diameter was 
70 nm. Successful BP functionalization was also confirmed by 
energy dispersive X-ray spectroscopy (Figure S1, Supporting 
Information) as well as by IR spectroscopy (Figure 1d–f). The 
IR spectrum of the precursor Gd2O3 nanoparticles contains a 
distinctive peak at 2871 cm−1 corresponding to the stretching 
and bending of the methylene chain (CH2), a sharp band 
at 1084 cm−1 is assigned to the CO stretch, and the broad peak 
at 3100–3500 cm−1 corresponds to the OH stretch (Figure 1d). 
After GPTES coating, the symmetric epoxy ring deforma-
tion gives an IR peak in the IR at 788 cm−1, while the sharp 
band at 1248 cm−1 is associated with ring stretching vibrations 
(Figure 1e), matching previous studies of epoxide derivatives.[9] 
In the BP functionalized derivative, the appearance of peaks at 
1057 and 1521 cm−1 corresponds to the phosphonate groups 
and to the NH amide bonds respectively, confirming that the 
BP functionalization had been achieved (Figure 1f). The charac-
terization data for the GBCAs-BP are summarized in Table S1 
in the Supporting Information.
An optimal GBCA for clinical applications needs to have 
high relaxivity showing significantly shortened T1 relaxation 
values, which will allow the required signal enhancement to be 
achieved at a low enough concentration, and to be incorporated 
into the CPC without significantly disrupting the properties 
of the material. In vitro relaxivity studies were performed on 
the gadolinium nanoparticles with measurements at different 
magnetic field strengths that are typically found in clinical and 
preclinical settings (using 3T clinical scanner and 11.7T small 
bore system across a range of concentrations) (Figure 2 and 
Table S2, Supporting Information). Increasing the magnetic field 
strength is known to reduce T1 relaxivity for gadolinium(III) 
agents and, in many cases, increase the T2 relaxivity.[11]
Adv. Healthcare Mater. 2018, 7, 1800202
Figure 2. Characterization of the relaxation properties of the particles, their affinity toward the CPC mineral phase, and in vitro cytotoxicity. a,b) plot 
of 1/T1 and 1/T2 measured at 3 T, c,d) plot of 1/T1 and 1/T2 measured at 11.7 T as a function of GBCAs-BP concentration, respectively. r1 and r2 were 
calculated from the slope (n = 3). e) The T1-weighted MR images of a phantom with GBCAs-BP are shown at different concentrations (image recorded 
simultaneously). f) The binding profile of GBCAs-BP after 2, 6, and 24 h incubation with CPC cylindrical blocks (n = 3). g) Dimethylthiazol-2-yl-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl) tetrazolium assay performed on HOb (n = 3). *p < 0.05. Results are represented as a mean ± SD. p-values 
were calculated using one-way analysis of variance (ANOVA) with Tukey’s post hoc test.
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To be an effective T1 contrast agent, the nanoparticles should 
possess an ultrasmall core size and a hydrophilic coating sur-
face, this ensures that a large surface area of Gd2O3 is avail-
able to directly interacts with the surrounding water molecules 
and that they can rapidly exchange. Aqueous suspensions of 
the GBCAs-BP with a concentration of gadolinium(III) var-
ying between 0.2 and 2 × 10−3 m were scanned using inversion 
recovery for T1.[12] The linear fit of the data acquired versus the 
concentration of gadolinium(III), gives an overall relaxation rate 
indicating the efficiency of the contrast agent under the experi-
mental conditions. Specifically, GBCAs-BP showed an r1 equal 
to 15.41 × 10−3 m−1 s−1 at 3 T which is almost four times higher 
than the commercially available contrast agents (e.g., Magne-
vist or Omniscan).[11] Furthermore, the nanoparticles showed 
only a slight decrease of T1 relaxivity at 11.7 T, with r1 equal to 
13.44 × 10−3 m−1 s−1, while the final r2/r1 ratio remained similar 
at the two magnetic field strengths (r2/r1 = 4.77 at 3 T and r2/ 
r1 = 4.30 at 11.7 T) (Figure 2a–d and Table S2, Supporting Infor-
mation). The images of the GBACs-BP phantoms at different 
concentrations (Figure 2e) show the dominant T2 effect at 
higher contrast agent concentrations, indicating that the lower 
concentrations of GBCAs-BP (i.e., 1.5 × 10−3 m) is effective for a 
T1-weighted signal enhancement, which correlates with appro-
priate amounts to incorporate into CPC materials. In vitro 
binding tests demonstrated the high affinity of the GBCAs-BP 
(>95%) toward the CPC material at up to 24 h incubation time 
(Figure 2f) with no dissociation observed.
In vitro cytotoxicity studies were performed on pri-
mary human osteoblast (HOb) showing a negative effect 
on cell viability at high concentrations of the GBCAs-BP 
(i.e., > 100 × 10−6 m, Figure 2g). However, at low concentrations 
(0.1, 1, and 10 × 10−6 m) of the GBCAs-BP showed a beneficial 
effect on the HOb viability when compared to the nontreated 
cells (i.e., the internal control) as the nanoparticles induced 
cell proliferation (Figure 2g). Such findings not only suggested 
a nontoxic and concentration-dependent effect of the GBCAs-
BP nanoparticles, but also highlighted the beneficial potential 
of the BP functionalization on the cell behavior. This is as 
expected and in line with the known properties of bisphospho-
nate compounds, and the role of BP derivatives on the prolifer-
ation and differentiation of HOb cells has been investigated.[13] 
With this study, we confirm the beneficial effect of BP-coated 
nanoparticles derivatives on HOb and support further investi-
gation of this strategy for bone regenerative applications.
Once the GBCAs-BP particles were synthesized, charac-
terized, and found to have appropriate properties to enhance 
contrast in the application, it was important to determine the 
concentration of the nanoparticle contrast agent that could be 
added to the CPC composite without affecting its final handling 
and mechanical properties, and so preliminary studies were 
carried out (data not shown). Our findings corroborated the 
reports in the available literature on CPC doping and suggested 
that adding GBCAs-BP into the CPC composite with a final 
concentration of 1 wt/wt% would be appropriate. Furthermore, 
this contrast agent concentration would allow direct compar-
ison with the longitudinal in vivo imaging performances of the 
CPC-GBCAs-BP construct with the CPC composite doped with 
a commercial molecular gadolinium(III) contrast that has been 
described in previous studies.[7] The handling and mechanical 
properties, as well as the imaging features of the prepared 
CPC-GBCAs-BP nanocomposite, were investigated in vitro 
(Figure 3). The setting time assessment showed an increase 
in the initial and final setting profiles for the CPC-GBCAs-BP 
nanocomposite when compared to the nonlabeled composite 
(Figure 3a). It is known that by increasing the alendronate 
concentration in the CPC matrix the setting time increases 
as a consequence of the coordination interaction between the 
phosphonate ions and the calcium salts present in the solution, 
preventing their rapid incorporation into the crystal lattice and 
hindering the crystal growth and agglomeration.[14] The internal 
CPC control consisting of unfunctionalized nanoparticles (i.e., 
CPC-GBCAs), confirmed the role of the BP groups increasing 
the setting time of the CPC nanocomposite. However, the set-
ting features observed for the CPC-GBCAs-BP nanocomposite, 
i.e., initial time of 11 min and final time of 23 min, are still 
acceptable for clinical use.[15] The addition of the GBCAs-
BP was shown to increase the compressive strength and the 
E-modulus of the final composite statistically when compared 
to the nonlabeled cement (Figure 3b,c). The nonfunctionalized 
control (i.e., CPC-GBCAs) showed no differences in properties 
when compared to the CPC-GBCAs-BP nanocomposite, sug-
gesting that the mechanical properties were improved by the 
nanoparticles themselves rather than the BP functionalization 
on the surface. As measured by Brunauer–Emmett–Teller anal-
ysis, the CPC composite consisted of a nanoporous structure 
(pore width = 18.8 nm, surface area = 9.7 m2 g−1) with a reduc-
tion in pore size and surface area observed for the CPC-GBCAs-
BP nanocomposite (pore width = 14.3 nm, surface area = 
7.4 m2 g−1) possibly suggesting that the added GBCAs-BP were 
filling these pores to give rise to a more dense microstructure. 
The final mechanical properties of the CPC-GBCAs-BP were 
comparable with most of the studied calcium phosphate-based 
compositions; hence, it is suitable as cancellous bone filler.[16] 
Finally, the GBCAs-BP labeled CPC composition showed excel-
lent hydraulic properties as all the pastes could be extruded 
from the syringe through a 1.7 mm orifice in less than 30 sec 
by applying a minimal injection force (see Figure 3d).
Gadolinium has a high atomic number (Z = 64) and high 
X-ray attenuation per mass (3.11 cm2 g−1 at100 keV) and it has 
been used as CT contrast agent especially for angiography and 
aortography applications.[17] Therefore, the capability of the 
GBCAs-BP to enhance the CT contrast of the nonlabeled CPC 
composite was also investigated. Gray value quantification, 
based on in vitro micro-CT acquisition, reported a shift of the 
values showing a darkening of the CPC-GBCAs-Bp nanocom-
posite versus the control (Figure 3e,f). The enhancement of the 
CT contrast of a calcium phosphate-based composite by using 
gadolinium-based nanoparticles could offer additional informa-
tion, especially in cases of a multimodal imaging assessment of 
the CPC degradation (i.e., using both MRI and CT).
Finally, the MRI properties of the CPC-GBCAs-BP material 
were investigated after injection in pig bone blocks (Figure 3g) 
and compared to the nonlabeled CPC. ZTE-MRI acquisi-
tions of the samples containing GBCAs-BP, performed at 
11.7 T, showed a typical T2* shortening effect which resulted 
in an imaging artifact that led to a sample size overestima-
tion (Figure 3h). It is known that gadolinium(III) not only has 
a T1-shorthening effect, but also a T2 (T2*) shortening effect, 
Adv. Healthcare Mater. 2018, 7, 1800202
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depending on its concentration.[18] Qualitative comparison of 
our results with previous studies where the CPC was combined 
with commercially available molecular gadolinium(III) agents 
(i.e., Gd-DTPA/MagneVist) the GBCA-BP nanoparticles showed 
enhanced contrast with a higher signal intensity, confirming 
the superior imaging performance of our nanoparticles.[7] The 
contrast of CPC without nanoparticles supplementation can 
be qualitatively observed; however, it has been already proved 
to be insufficient for in vivo translation (Figure 3h).
To assess the longitudinal MRI and CT imaging behavior 
of the CPC-GBCAs-BP nanocomposite, an in vivo study was 
performed (Figure S2, Supporting Information). Respectively, 
labeled and nonlabeled CPCs were injected in a cylindrical defect 
prepared in a rat condyle, which is a well-established nonload 
bearing model commonly used for testing biomaterials.[19] MRI 
and CT acquisitions were performed postsurgery (i.e., day 0), 
and at 4 and 8 weeks with the data shown in Figure 4. After 
the surgeries, high-resolution ZTE images of the CPC-GBCAs-
BP showed a T2 weighted signal, which resulted in an implant 
size overestimation (Figure 4a). In contrast, the CPC composite 
without contrast agent appeared as a dark hypodense region on 
ZTE MR images. Such findings were in line with our in vitro 
assessments (Figure 3h). Longitudinal monitoring showed the 
superior imaging performances of the CPC-GBCAs-BP com-
pared to the nonlabeled CPC as in the former case it was pos-
sible to clearly identify the implanted material at every time 
point. Moreover, at 4 weeks postsurgery, the implant size of the 
CPC-GBCAs-BP nanocomposite was observed to have slightly 
decreased, while in the center of the implant a brighter area 
appeared. Interestingly, the relative intensity of this bright 
region increased at 8 weeks (Figure 4a). It is known that GBCAs 
can lead to a competitive behavior between T1 and T2 short-
ening effects resulting in a bright or dark signal respectively.[20] 
Such a competitive effect may explain the appearance of the 
brighter region in the central part of the implant, although vari-
ations in agent concentration could also be an important factor 
determining the change in signal intensity.
CT images showed enhanced signal intensity in the case 
of the CPC/GBCAs-BP nanocomposite when compared either 
to the nonlabeled CPC or to the natural bone phase. The CT 
signal enhancement persisted for all of the time points and 
allowed a facile morphological assessment of the implant shape 
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Figure 3. Characterization of the handling and imaging properties of the CPC-GBCAs-BP. a) setting time (n = 3), b) compressive strength (n = 6), and 
c) E-modulus (n = 6) of the CPC composite without contrast agent, combined with GBCAs and with GBCAs-BP, respectively. d) injectability (n = 3) 
trend of the CPC with and without GBCAs-BP. e) gray value distribution (n = 3) of the CPC with and without GBCAs-BP obtained from µCT assess-
ment (note the pronounced shift to the left from the CPC composition with GBCAs-BP). f) 2D reconstruction of pre-set cylinders of the CPC with (on 
the top) and without GBCAs-BP (on the bottom) obtained from µCT acquisition (note the clear visual difference in color of the CPC with and without 
contrast agent). g-I) Overview of a pig jaw bone block with a cylindrical defect (3 × 3 mm). g-II—III) CPC with and without GBCAs-BP was used to fill 
the defect. h) ZTE-MR images of CPC with and without GBCAs-BP after injection in pig bone blocks (n = 3). For each sample, the axial and sagittal 
views are shown respectively (note the shape overestimation caused by the added contrast agent). *p < 0.05. Results are represented as a mean ± SD. 
p-values were calculated using one-way ANOVA with Tukey’s post hoc test.
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and volume (Figure 4b). Interestingly, 4 weeks postsurgery, 
the CT acquisitions of the implanted CPC-GBCAs-BP showed 
hetero geneity in material density. Specifically, the central part 
of the implant appeared to be less dense compared to the outer 
area. Such findings were in line with the MRI acquisitions and 
confirmed that there is a lower GBCAs-BP concentration in the 
central part of the CPC composite. Moreover, the comparison 
of these findings with longitudinal studies performed in a 
similar animal model, but with nonfunctionalized contrast 
agents (i.e., molecular gadolinium(III) agents or superpara-
magnetic iron oxide particles), proved the feasibility of our 
strategy in prolonging the residence of the contrast agent in the 
CPC matrix up to at least 8 weeks postsurgery.[8,20] One poten-
tial issue is the observed implant size overestimation on MR 
Figure 4. CPC composite with and without GBCAs-BP after injection in a rat condyle defect (n = 6). a) The ZTE MR images and b) the CT acquisitions 
are shown, respectively. From the top to the bottom, the axial view of the same leg after surgery, at 4 and 8 weeks postsurgery are shown, respectively. 
Note yellow dashed circles that indicate the difference in size between CPC with and without GBCAs-BP. Green arrows indicate the bright region that 
appears in the middle of the implant on the MRI acquisitions after 4 weeks from the surgery. The bright region corresponds on the CT images to a 
less dense material. Red arrow indicates the CPC that become indistinguishable from the surrounding bone after 8 weeks from implantation in vivo. 
c) Histological sections after elastic van gieson staining (scale bar 500 µm). The insets show the new bone formation quantification based on the histo-
logical sections. The red dashed lines indicate the bone volume observed in the nontreated samples. Results are represented as a mean ± SD. p-values 
were calculated using Student’s t-test with Welch’s corrections. No significant differences between the groups were found (p < 0.05).
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images; however, this property could be considered an advan-
tage for detection especially when small amounts of the cement 
need to be identified in the body. For instance, extravertebral 
CPC extrusion is a common problem after vertebroplasty that 
causes pain and neurological complications.[21] In these cir-
cumstances, the size-overestimation effect could serve to iden-
tify leakage of small amount of cement outside of the surgical 
site, hence supporting the surgeon in the postoperative neuro-
logical examination.
Histological assessment was performed 8 weeks after sur-
geries and showed a direct contact between bone and the 
cement, without sign of inflammation or fibrous encapsula-
tion (see Figure 4c and Figure S3, Supporting Information). 
BP-loaded CPCs have been used to increase bone augmenta-
tion after in vivo implantation in femora and vertebra of osteo-
porotic rats. Specifically, release of BP derivatives from the CPC 
phase resulted in an increased bone density in the immediate 
proximity of the implant (i.e., in an area from 0.4 to 0.7 mm 
far the cement).[22] Our histological findings were in line with 
these previous studies indicating higher bone density may be 
present around the implant when compared to the CPC com-
position without BP components (Figure 4c). However, statis-
tical t-testing did not show significant differences in new bone 
formation between the experimental groups of this size and 
so further studies are necessary to validate this observation 
(Figure 4c).
One area of further study that is ongoing is to look at the 
release profile in vivo and the biodistribution of the GBCAs-
BP on release from the CPC composite. Methods for radiola-
beling are under investigation to determine a valid quantita-
tive tracking. Previous studies have showed that GBCAs do 
not undergo to intracellular accumulation and are generally 
excreted by the hepatobiliary or renal systems.[23] The decrease 
in MRI and CT signal over time and the absence of back-
ground signals in the surrounding tissues indicate that any 
GBCAs-BP released from the materials did not accumulate 
and were eliminated from the body. Histological assessments 
using elemental analysis (e.g., inductively coupled plasma mass 
spectroscopy (ICP-MS) and inductively coupled plasma atomic 
emission spectroscopy (ICP-AES)) and TEM on tissue samples 
from different organs (e.g., kidney, liver, spleen, and brain) 
can provide useful and unequivocal information regarding the 
bioaccumulation of the nanoparticles once released from the 
implanted CPC. Additionally, hemolytic tests to investigate the 
lysis of erythrocytes in response to the release of the nanoparti-
cles from the CPC in the bloodstream are suggested to further 
investigate their biocompatibility and potential use for medical 
applications.[24]
The overall profile of the ultrasmall Gd2O3 nanoparticles 
that have been designed and produced in this work offers a 
significant advance over the current state-of-the-art for longitu-
dinal imaging of calcium phosphate cements. The key image 
acquisition features are effective multiple modality imaging 
(combining contrast in both MR and CT from a single agent) 
and high relaxivity across appropriate MR field strengths. A 
feature of equally high importance for longitudinal studies is 
the high affinity for the cement material, which is due to the 
bisphosphonate coating added to the silica layer.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
Acknowledgements
S.M. and A.E.K. contributed equally to this work. S.M., A.E.K., and W.D. 
received funding from People Programme (Marie Curie Action) of the 
European Union’s Seventh Framework Programme FP7/2007-2013/ under 
REA grant agreement No. 607868 (iTERM). The authors are grateful for 
the technical support to Drs. Vincent Cuijpers, Martijn Martens, Natasja 
van Dijk, Danny Gerrits, Andor Veltien, and Bianca Lammers van der 
Weem. The animal study was performed after the approval of the Animal 
Ethics Committee for the care and use of laboratory animals (RU-DEC 
number 2015-0035) and in agreement with the standards of the Radboud 
University Medical Center, Nijmegen, the Netherlands.
Conflict of Interest
The authors declare no conflict of interest.
Keywords
biphosphonate, calcium phosphate cements, computed tomography, 
gadolinium-based contrast agents, magnetic resonance imaging
Received: February 23, 2018
Revised: May 22, 2018
Published online: August 17, 2018
[1] a) S. Pina, J. M. Oliveira, R. L. Reis, Adv. Mater. 2015, 27, 1143; 
b) G. S. Sailaja, P. Ramesh, S. Vellappally, S. Anil, H. K. Varma, 
J. Biomed. Sci. 2016, 23, 77.
[2] a) L. E. Smith, R. Smallwood, S. Macneil, Microsc. Res. Tech. 2010, 
73, 1123; b) A. A. Appel, M. A. Anastasio, J. C. Larson, E. M. Brey, 
Biomaterials 2013, 34, 6615; c) S. Y. Nam, L. M. Ricles, L. J. Suggs, 
S. Y. Emelianov, Tissue Eng., Part B 2015, 21, 88.
[3] a) W. Habraken, P. Habibovic, M. Epple, M. Bohner, Mater. 
Today 2016, 19, 69; b) J. Zhang, W. Liu, V. Schnitzler, F. Tancret, 
J.-M. Bouler, Acta Biomater. 2014, 10, 1035; c) R. O’Neill, 
H. O. McCarthy, E. Montufar, M. P. Ginebra, D. I. Wilson, 
A. Lennon, N. Dunne, Acta Biomater. 2017, 50, 1.
[4] a) S. Larsson, J. Orthop. Trauma 2010, 24, S41; b) F. D. Beaman, 
L. W. Bancroft, J. J. Peterson, M. J. Kransdorf, D. M. Menke, 
J. K. DeOrio, Radiographics 2006, 26, 373; c) S. Mastrogiacomo, W. Dou, 
O. Koshkina, O. C. Boerman, J. A. Jansen, A. Heerschap, M. Srinivas, 
X. F. Walboomers, ACS Appl. Mater. Interfaces 2017, 9, 22149.
[5] a) M. Ventura, O. C. Boerman, C. de Korte, M. Rijpkema, 
A. Heerschap, E. Oosterwijk, J. A. Jansen, X. F. Walboomers, Tissue 
Eng., Part B 2014, 20, 578; b) M. D. Robson, P. D. Gatehouse, 
M. Bydder, G. M. Bydder, J. Comput. Assisted Tomogr. 2003, 27, 825; 
c) J. E. Holmes, G. M. Bydder, Radiography 2005, 11, 163.
[6] a) T. J. Fraum, D. R. Ludwig, M. R. Bashir, K. J. Fowler, J. Magn. 
Reson. Imaging 2017, 46, 338; b) Z. Zhou, Z. R. Lu, Wiley Inter-
discip. Rev.: Nanomed. Nanobiotechnol. 2013, 5, 1; c) G. Singh, 
B. H. McDonagh, S. Hak, D. Peddis, S. Bandopadhyay, 
I. Sandvig, A. Sandvig, W. R. Glomm, J. Mater. Chem. B 2017, 5, 
418.
www.advancedsciencenews.com www.advhealthmat.de
1800202 (9 of 9) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Healthcare Mater. 2018, 7, 1800202
[7] Y. Sun, M. Ventura, E. Oosterwijk, J. A. Jansen, X. F. Walboomers, 
A. Heerschap, Tissue Eng., Part C 2013, 19, 281.
[8] a) R. A. Nadar, N. Margiotta, M. Iafisco, J. J. P. vad der beucken, 
O. C. Boerman, S. C. G. Leeuwenburgh, Adv. Healthcare Mater. 2017, 
6, 8; b) L. E. Cole, T. Vargo-Gogola, R. K. Roeder, Adv. Drug Delivery 
Rev. 2016, 99, 12; c) V. Kubicek, J. Rudovsky, J. Kotek, P. Hermann, 
L. Vander Elst, R. N. Muller, Z. I. Kolar, H. T. Wolterbeek, 
J. A. Peters, I. Lukes, J. Am. Chem. Soc. 2005, 127, 16477; 
d) L. Sandiford, A. Phinikaridou, A. Protti, L. K. Meszaros, X. Cui, 
Y. Yan, G. Frodsham, P. A. Williamson, N. Gaddum, R. M. Botnar, 
P. J. Blower, M. A. Green, R. T. de Rosales, ACS Nano 2013, 7, 500.
[9] M. Cano, G. de la Cueva-Mendez, Chem. Commun. 2015, 51, 3620.
[10] G. Azizian, N. Riyahi-Alam, S. Haghgoo, H. R. Moghimi, 
R. Zohdiaghdam, B. Rafiei, E. Gorji, Nanoscale Res. Lett. 2012, 7, 
549.
[11] a) P. Caravan, C. T. Farrar, L. Frullano, R. Uppal, Contrast Media 
Mol. Imaging 2009, 4, 89; b) G. E. Hagberg, K. Scheffler, Contrast 
Media Mol. Imaging 2013, 8, 456.
[12] a) J. Fang, P. Chandrasekharan, X. L. Liu, Y. Yang, Y. B. Lv, C. T. Yang, 
J. Ding, Biomaterials 2014, 35, 1636; b) H. B. Na, T. Hyeon, J. Mater. 
Chem. 2009, 19, 6267; c) A. Louie, Chem. Rev. 2010, 110, 3146; 
d) M. Cho, R. Sethi, J. S. Narayanan, S. S. Lee, D. N. Benoit, 
N. Taheri, P. Decuzzi, V. L. Colvin, Nanoscale 2014, 6, 13637.
[13] O. Fromigue, J. J. Body, J. Endocrinol. Invest. 2002, 25, 539.
[14] a) Z. Jindong, T. Hai, G. Junchao, W. Bo, B. Li, W. B. Qiang, Ortho-
pedics 2010, 33, 561; b) S. Bose, S. Tarafder, Acta Biomater. 2012, 
8, 1401; c) L. M. Grover, U. Gbureck, A. M. Young, A. J. Wright, 
J. E. Barralet, J. Mater. Chem. 2005, 15, 4955; d) L. M. Grover, 
A. J. Wright, U. Gbureck, A. Bolarinwa, J. Song, Y. Liu, D. F. Farrar, 
G. Howling, J. Rose, J. E. Barralet, Biomaterials 2013, 34, 6631.
[15] K. L. Low, S. H. Tan, S. H. Zein, J. A. Roether, V. Mourino, 
A. R. Boccaccini, J. Biomed. Mater. Res., Part B 2010, 94, 273.
[16] J. Zhang, W. Liu, V. Schnitzler, F. Tancret, J. M. Bouler, Acta Bio-
mater. 2014, 10, 1035.
[17] a) N. Lee, S. H. Choi, T. Hyeon, Adv. Mater. 2013, 25, 2641;  
b) J. W. Henson, R. G. Nogueira, D. J. Covarrubias, R. G. Gonzalez, 
M. H. Lev, AJNR Am. J. Neuroradiol. 2004, 25, 969; c) S. Chryssidis, 
R. P. Davies, M. L. Tie, Australas. Radiol. 2002, 46, 97.
[18] a) M.-J. Lee, M.-J. Kim, C.-S. Yoon, S. Y. Song, K. Park, W. S. Kim, 
Korean J. Radiol. 2011, 12, 358; b) A. T. Tirkes, M. A. Rosen, 
E. S. Siegelman, Int. J. Cardiovasc. Imaging 2003, 19, 151; 
c) M. Kanematsu, M. Matsuo, Y. Shiratori, H. Kondo, H. Hoshi, 
I. Yasuda, H. Moriwaki, Am. J. Roentgenol. 2002, 178, 755;  
d) V. Y. Kuperman, M. T. Alley, J. Magn. Reson. Imaging 1999, 9, 172.
[19] M. Bongio, J. J. van den Beucken, S. C. Leeuwenburgh, J. A. Jansen, 
J. Tissue Eng. Regener. Med. 2015, 9, 191.
[20] a) M. Ventura, Y. Sun, V. Rusu, P. Laverman, P. Borm, A. Heerschap, 
E. Oosterwijk, O. C. Boerman, J. A. Jansen, X. F. Walboomers, 
Tissue Eng., Part C 2013, 19, 405; b) M. Ventura, Y. Sun, S. Cremers, 
P. Borm, Z. T. Birgani, P. Habibovic, A. Heerschap, P. M. van der 
Kraan, J. A. Jansen, X. F. Walboomers, Biomaterials 2014, 35, 2227.
[21] a) M. Nakano, N. Hirano, H. Ishihara, Y. Kawaguchi, K. Matsuura, 
J. Neurosurg. 2005, 2, 27; b) X. Wang, J. Ye, Y. Wang, Acta Biomater. 
2007, 3, 757.
[22] a) E. Verron, O. Gauthier, P. Janvier, P. Pilet, J. Lesoeur, B. Bujoli, 
J. Guicheux, J. M. Bouler, Biomaterials 2010, 31, 7776; b) E. Verron, 
M.-L. Pissonnier, J. Lesoeur, V. Schnitzler, B. H. Fellah, H. Pascal-
Moussellard, P. Pilet, O. Gauthier, J.-M. Bouler, Acta Biomater. 
2014, 10, 4887.
[23] a) S. Aime, P. Caravan, J. Magn. Reson. Imaging 2009, 30, 1259; 
b) D. Kryza, J. Taleb, M. Janier, L. Marmuse, I. Miladi, P. Bonazza, 
C. Louis, P. Perriat, S. Roux, O. Tillement, C. Billotey, Bioconjugate 
Chem. 2011, 22, 1145.
[24] a) B. J. Marquis, S. A. Love, K. L. Braun, C. L. Haynes, Analyst 
2009, 134, 425; b) S. A. Love, M. A. Maurer-Jones, J. W. Thompson, 
Y. S. Lin, C. L. Haynes, Annu. Rev. Anal. Chem. 2012, 5, 18;  
c) M. A. Dobrovolskaia, J. D. Clogston, B. W. Neun, J. B. Hall, 
A. K. Patri, S. E. McNeil, Nano Lett. 2008, 8, 2180.
